Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

666

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

February 26, 2025

Study Completion Date

February 6, 2026

Conditions
Lung Cancer, Non-Small Cell
Interventions
DRUG

Niraparib

Niraparib will be administered.

BIOLOGICAL

Pembrolizumab

Pembrolizumab will be administered

DRUG

Placebo

Matching placebo will be administered

Trial Locations (190)

8

GSK Investigational Site, Dublin

1011

GSK Investigational Site, Lausanne

1083

GSK Investigational Site, Budapest

1200

GSK Investigational Site, Brussels

1470

GSK Investigational Site, Lrenskog

1602

GSK Investigational Site, Florida

1632

GSK Investigational Site, Sofia

1900

GSK Investigational Site, La Plata

2045

GSK Investigational Site, Törökbálint

2148

GSK Investigational Site, Blacktown

2650

GSK Investigational Site, Edegem

2800

GSK Investigational Site, Tatabánya

3000

GSK Investigational Site, Leuven

3084

GSK Investigational Site, Heidelberg

3200

GSK Investigational Site, Gyöngyös

3350

GSK Investigational Site, Ballarat

4004

GSK Investigational Site, Plovdiv

4500

GSK Investigational Site, Panagyurishte

5800

GSK Investigational Site, Pleven

7000

GSK Investigational Site, Hobart

7002

GSK Investigational Site, Rousse

8800

GSK Investigational Site, Roeselare

10016

GSK Investigational Site, Mineola

10043

GSK Investigational Site, Orbassano to

11526

GSK Investigational Site, Athens

11528

GSK Investigational Site, Athens

12462

GSK Investigational Site, Athens

13125

GSK Investigational Site, Berlin

13620

GSK Investigational Site, Seongnam-si Gyeonggi-do

15006

GSK Investigational Site, A Coruña

15125

GSK Investigational Site, Athens

15212

GSK Investigational Site, Pittsburgh

15562

GSK Investigational Site, Athens

17007

GSK Investigational Site, Girona

20122

GSK Investigational Site, Milan

20132

GSK Investigational Site, Milan

20133

GSK Investigational Site, Milan

20251

GSK Investigational Site, Hamburg

20900

GSK Investigational Site, Monza

22030

GSK Investigational Site, Edirne

22031

GSK Investigational Site, Fairfax

22927

GSK Investigational Site, Großhansdorf

26500

GSK Investigational Site, Pátrai

GSK Investigational Site, Rio Patras

28009

GSK Investigational Site, Madrid

28027

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

28050

GSK Investigational Site, Madrid

28207

GSK Investigational Site, Charlotte

28222

GSK Investigational Site, Madrid

29010

GSK Investigational Site, Málaga

29609

GSK Investigational Site, Brest

30265

GSK Investigational Site, Newnan

30322

GSK Investigational Site, Atlanta

30459

GSK Investigational Site, Hanover

31008

GSK Investigational Site, PamplonaNavarra

31059

GSK Investigational Site, Toulouse

32003

GSK Investigational Site, Tallahassee

33081

GSK Investigational Site, Aviano PN

34662

GSK Investigational Site, Istanbul

35016

GSK Investigational Site, Las Palmas de Gran Canar

35033

GSK Investigational Site, Rennes

37045

GSK Investigational Site, Verona

37203

GSK Investigational Site, Nashville

37404

GSK Investigational Site, Chattanooga

38043

GSK Investigational Site, Grenoble

39008

GSK Investigational Site, Santander

41110

GSK Investigational Site, Larissa

42551

GSK Investigational Site, Velbert

44093

GSK Investigational Site, Saint-Herblain

45147

GSK Investigational Site, Essen

50009

GSK Investigational Site, Zaragoza

50134

GSK Investigational Site, Florence

52242

GSK Investigational Site, Iowa City

53113

GSK Investigational Site, Bonn

54007

GSK Investigational Site, Thessaloniki

54622

GSK Investigational Site, Thessaloniki

54645

GSK Investigational Site, Thessaloniki

56124

GSK Investigational Site, Pisa

57001

GSK Investigational Site, Pylaia Thessaloniki

57010

GSK Investigational Site, Thessaloniki

58675

GSK Investigational Site, Hemer

59037

GSK Investigational Site, Lille

60488

GSK Investigational Site, Frankfurt

60714

GSK Investigational Site, Niles

64460

GSK Investigational Site, Monterrey

67200

GSK Investigational Site, Strasbourg

69126

GSK Investigational Site, Heidelberg

70124

GSK Investigational Site, Bari

70376

GSK Investigational Site, Stuttgart

71110

GSK Investigational Site, Heraklion Crete

72560

GSK Investigational Site, Puebla Puebla

75014

GSK Investigational Site, Paris

75018

GSK Investigational Site, Paris

75090

GSK Investigational Site, Sherman

75246

GSK Investigational Site, Dallas

76712

GSK Investigational Site, Waco

77479

GSK Investigational Site, Sugar Land

78217

GSK Investigational Site, San Antonio

80128

GSK Investigational Site, Lone Tree

80131

GSK Investigational Site, Napoli

80336

GSK Investigational Site, München

81925

GSK Investigational Site, München

82131

GSK Investigational Site, Gauting

83056

GSK Investigational Site, Toulon

83100

GSK Investigational Site, Avellino

90017

GSK Investigational Site, Los Angeles

92835

GSK Investigational Site, Fullerton

94010

GSK Investigational Site, Créteil

95123

GSK Investigational Site, Catania

121309

GSK Investigational Site, Moscow

140044

GSK Investigational Site, Córdoba

197022

GSK Investigational Site, Saint Petersburg

197758

GSK Investigational Site, Saint Petersburg

200542

GSK Investigational Site, Craiova

230018

GSK Investigational Site, Montería

300239

GSK Investigational Site, Timișoara

400015

GSK Investigational Site, Cluj-Napoca

440055

GSK Investigational Site, Satu Mare

603081

GSK Investigational Site, Nizhny Novgorod

644013

GSK Investigational Site, Omsk

700483

GSK Investigational Site, Iași

5360000

GSK Investigational Site, Temuco

5600520

GSK Investigational Site, Bogotá

7500653

GSK Investigational Site, Santiago

7500921

GSK Investigational Site, Santiago

06360

GSK Investigational Site, Norwich

01655

GSK Investigational Site, Worcester

10016-4744

GSK Investigational Site, New York

C1125ABD

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

R8324CVE

GSK Investigational Site, Cipoletti Rio Negro

C1012AAR

GSK Investigational Site, Ciudad Autonoma de Buenos Aire

C1426AGE

GSK Investigational Site, Ciudad Autonoma de Buenos Aire

X5004FHP

GSK Investigational Site, Córdoba

S2000DSV

GSK Investigational Site, Rosario

30110-022

GSK Investigational Site, Belo Horizonte

29308-014

GSK Investigational Site, Cachoeiro de Itapemirim

80040-170

GSK Investigational Site, Curitiba

90610-000

GSK Investigational Site, Porto Alegre

22250-905

GSK Investigational Site, Rio de Janeiro

01308-901

GSK Investigational Site, São Paulo

01509-010

GSK Investigational Site, São Paulo

38408-150

GSK Investigational Site, Uberlândia

06120

GSK Investigational Site, Halle

07747

GSK Investigational Site, Jena

115 27

GSK Investigational Site, Athens

185 37

GSK Investigational Site, Athens

185 47

GSK Investigational Site, Neo Faliro

H-1122

GSK Investigational Site, Budapest

T12 DFK4

GSK Investigational Site, Cork

00168

GSK Investigational Site, Roma

03100

GSK Investigational Site, Mexico City

06700

GSK Investigational Site, Mexico City

CP 14080

GSK Investigational Site, Mexico City

5223 GZ

GSK Investigational Site, 's-Hertogenbosch

3813 TZ

GSK Investigational Site, Amersfoort

1066 CX

GSK Investigational Site, Amsterdam

7512 KZ

GSK Investigational Site, Enschede

6229 HX

GSK Investigational Site, Maastricht

3543 AZ

GSK Investigational Site, Utrecht

8025 AB

GSK Investigational Site, Zwolle

N-3004

GSK Investigational Site, Drammen

N-0450

GSK Investigational Site, Oslo

Lima 34

GSK Investigational Site, Lima

15-540

GSK Investigational Site, Bialystok

90-338

GSK Investigational Site, Lodz

10-357

GSK Investigational Site, Olsztyn

011654

GSK Investigational Site, Bucharest

022328

GSK Investigational Site, Bucharest

105 229

GSK Investigational Site, Moscow

463-712

GSK Investigational Site, Seongnam-si

05505

GSK Investigational Site, Seoul

08308

GSK Investigational Site, Seoul

443-721

GSK Investigational Site, Suwon Kyunggi-do

08025

GSK Investigational Site, Barcelona

08035

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

SE-801 87

GSK Investigational Site, Gävle

SE-171 76

GSK Investigational Site, Stockholm

SE-751 85

GSK Investigational Site, Uppsala

06010

GSK Investigational Site, Ankara

06100

GSK Investigational Site, Ankara

06520

GSK Investigational Site, Ankara

BH7 7DW

GSK Investigational Site, Bournemouth

DD1 9SY

GSK Investigational Site, Dundee

HA6 2RN

GSK Investigational Site, Middlesex

OX3 7LJ

GSK Investigational Site, Oxford

LL13 7TD

GSK Investigational Site, Wrexham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04475939 - Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter